Nice! a small perk, but hopefully it will help to keep shorts away. This is not more than $7M so it hardly makes a dent in their cash reserves...annualized $28M
Check out Free Cash Flow Steelcity....they make tons of cash to pay off debt...they already paid down at least $800M in one year.
I see a beautiful bull flag forming on the 5min chart. I haven't seen that at all in 5 days. I get the feeling today we break out above $29. hope they are not playing mind games and the technicals rule.
2013 streaming winners and trends • 3:38 PM
The NPD Group is out with a SVOD Report which looks at streaming activity between January and October of this year.
The top movies streamed were The Hunger Games (LGF), The Avengers (DIS) and The Lorax (CMCSA) which are all movies aimed at younger audiences. The rankings go a long way toward explaining the tent-pole strategy of major studios.
Data on TV streaming showed the most activity was for Breaking Bad (AMCX), How I Met Your Mother (CBS), and AMC's The Walking Dead.
Netflix (NFLX) doesn't like to share ratings information, but NPD has the back of investors. Its data shows 11% of all Netflix users streamed Arrested Development at least once during the six weeks following its release. The mark was lower for House of Cards (5%) and Hemlock Grove (4%), although the penetration rates compare favorably to the broadcast world.
SVOD share of the total home video market rose to over 25% during the year.
Elliott Wave signal posted yesterday.12/16 3.34 close 27day pattern. Nice;let's see if it a start of a new upward trend!
Wave 1 marks the beginning of a new trend. It can be pointing upward or downward but it will be opposite to the previous trend. It is very hard to recognize the "first wave" at the start as usually at this time news floating around the market is generally bad and traders believe that the previous trend is still intact.
With the start of wave 1 volume might pickup as the prices rise. Volume should pick up, unless the bear trend ended with a capitulation move, and preferably is not very high. If it is, then the rally is more likely to be part of a bear market correction, with rampant short covering going on. A slow and steady price increase fits more closely to the start of a new bull market.
Here is the garbage report:
Unilife Corporation (UNIS): Top 10 Reasons
by Sonya Colberg, Senior Investigative Reporter - 12/4/2013 9:42:10 AM
While Unilife Corporation (NasdaqGM:UNIS) is flying, TheStreetSweeper lists the Top 10 reasons we’re bearish and short this over-hyped safety syringe company.
1. Novartis deal does not guarantee an ongoing revenue stream. The UNIS syringes will be used in a clinical trial, requiring few syringes. If Novartis enrolled 500 patients in the trial and injected each monthly using UNIS syringes, UNIS could look forward to only about $5,400 in revenue over a year. No wonder the UNIS press release doesn’t give financial details. It could easily take Novartis 3 to 5 years or more to complete clinical trials and get Food and Drug Administration approval before it would need to order any substantial number of syringes.
2. Even if the Novartis clinical trials pass with flying colors and get FDA approval, the company could easily decide to order syringes instead from safety syringe gorilla Becton Dickinson, controlling an estimated 70 percent of the syringe market. Besides, a whistle-blower lawsuit suggests UNIS lacks the protocol and safety procedures to pull off production of what sounds to be a more complicated syringe for Novartis.
3. Big announcements, bigger disappointments. Investors shouldn’t read into UNIS press releases that upcoming large revenue streams will necessarily occur. The press releases tend to list minimum volume purchases of UNIS syringes. These minimums are only to preserve exclusivity. No one is obligated to buy a certain volume.
4. UNIS CEO Alan Shortall has a goal of about a dozen contracts by year’s end. So far, five have been announced, including the Novartis deal and a Sanofi deal that are re-warmed old contracts. Is the company likely to average almost two contracts a week for the rest of the year? Highly unlikely.
5. Of the announced deals, three involve significant pharmaceutical companies – yet the press releases frequently mention contracts worth $5 million upfront initially plus milestone payments and “expected” revenue and other wishy-washy terms. Before investors hit the “buy” function, they should know what the company’s milestone payments are based on, what the volume production would be and when, plus the length of the ramp-up period. Investors need substance, not hype.
6. Mr. Shortall has a colorful background. We’re wondering who seed investor Roger Williamson really is and whether he actually exists. An Australian Supreme Court judge concluded the relationship contained “many unusual and unexplained features.” This figure emerged in a lawsuit – see the link here - brought by Mr. Shortall’s former girlfriend who claimed he failed to turn over UNIS shares he promised in return for loans she made to him. She was awarded $548,452 plus court costs.
7. Even with the announced deals, it’s not clear that UNIS has enough cash to last through the fiscal year ending in June, without raising more money in offerings. UNIS could use the recent spike to sell shares under their ATM (At the Market) agreement that allows shares to be sold at the drop of a hat. UNIS is burning through about $10 million per quarter and relied on selling stock or allowing employees to exercise options to the tune of $12.9 million last quarter – which gave UNIS $7.4 million cash on hand. Incidentally, independent auditors in October penned a going-down-in-flames note. The note warns investors that “the Company has incurred recurring losses from operations and has limited cash resources, which raise substantial doubt about its ability to continue as a going concern.”
8. Much to suggest Mr. Shortall tends to over-hype to make the company look better. He masterfully turned a recent poor financial report into a cheerleading session by saying, “I am pleased to have turned the corner. We are now entering a period of hyper-growth.” Given this history, can UNIS really produce hundreds of millions of prefilled safety syringes at a profit? The company has never done that.
9. Legal issues abound. Law firms are circling UNIS, filing or investigating class action complaints against the company and/or certain officers and directors. Misrepresentation, corporate waste and mismanagement are among the issues alleged or under investigation. Several are based primarily on accusations laid out in a securities fraud lawsuit filed by former supply chain vice president Talbot Smith, and the Forbes article “How is a $329 million syringe company still unprofitable after 11 years?”
10. Whistleblower Smith’s lawsuit alleges UNIS had employees pretend they were churning out syringes for investors and other visitors, when they were not. UNIS and Mr. Shortall deny such shenanigans occurred but we have spoken with employees who have dates and other details on these “Potemkin villages.”
Also, Mr. Smith charges that UNIS violated clean room and other FDA-related manufacturing procedural rules. UNIS denies the allegations. But we can’t help but wonder whether UNIS takes adequate safety precautions and why have they had such a massive turnover in their R&D staff.
Mr. Smith also filed a complaint with the UNIS board alleging Mr. Shortall directed employees to break into a terminated employee’s car and take his laptop. We have the police report – available here - showing this theft occurred.
Unilife drops 9% after Tilson says short to ValueWalk
Shares of Unilife are down 9% after Whitney Tilson said in an email to ValueWalk that he has a short position in the company. Tilson told ValueWalk that StreetSwepper "has done some good work exposing obvious frauds and/or promotions." StreetSwepper has reported cautiously on Unilife in the past. Shares of Unilife are down 9%, or 38c, to $4.11 in morning trading.
That is reason for the bear raid today
Seems like Endo has its own operating issues:
In January 2013, Endo Corporate Headquarters moves from Chadds Ford to a newly constructed building at the Atwater Campus in Malvern, PA.
On February 25, Rajiv De Silva is named President, Chief Executive Officer and a Director of Endo.
In June 2013, Endo announces strategic change to focus on providing quality healthcare products through distinct operating companies, and announces restructuring to improve operating margins.
Endo deal is a desperate one made by PATH. They screwed the shareholders. I bet the execs that stay on will get bonuses and options to make it worth their while for selling out on investors. What happened to the huge migraine with nausea market potential that they were raving about earlier this year?
Optinose rights - an inhaler for the same migraine/nausea market--- had this deal done by ANVR for ONLY North American rights:
Under the terms of the agreement, OptiNose received an upfront cash payment of $20 million and is eligible to receive certain shared development costs and up to an additional $90 million in total linked to the achievement of future clinical, regulatory and commercial milestones. In addition, if approved, Avanir will make tiered royalty payments based on net sales in North America.
So this is $110M + royalties into perpetuity just for North America
Surely Zecuity worldwide is worth more than $105 upfront and a measly $100M thereafter---it should reflect the present value of fair and reasonable royalty payments based on GLOBAL sales.
The most important thing to note: The ads will play automatically as they show up in users’ feeds — both on the desktop and on their phones. But they won’t play with sound unless someone clicks on them.
Here’s how Facebook describes the format to potential advertisers:
*Rather than having to click or tap on the content, videos will begin to play as they appear on screen — without sound — similar to how they behave when shared by friends now. If you don’t want to watch the video, you can simply scroll past it.
*If the video is clicked or tapped and played in full screen, the sound for that video will play, as well.
*At the end of the video, a carousel featuring two additional videos will appear, making it easy to discover more content from the same marketer.
*On mobile devices, all videos that begin playing as they appear on the screen will have been downloaded in advance when the device was connected to Wi-Fi — meaning this content will not consume data plans, even if you’re not connected to Wi-Fi at the time of playback.
Take a look at the Divergent Ad:
Facebook set to launch video ads • 5:03 AM
Facebook (FB) will reportedly announce the launch of video advertisements today and will start introducing them into users' newsfeeds on Thursday.
Among the first ads to play will be one for an upcoming Lions Gate (LGF) film called "Divergent."
It's not clear how much the commercials will cost, although a figure of $2M a day for all Facebook users aged 18-54 has been bandied about.
There's money to be made, especially with advertisers looking to use up unspent annual budgets, but a major question is whether they'll be a user backlash - the ads will play automatically, which some Facebook members might find exceptionally annoying.
Note that LGF went up 75% before we had our first down month. I believe we are setting up for similar movement in 2014.
Date LGF Price